Unitech Pharma AB announces today that it will provide Aprea AB with additional GMP manufacturing of APR-246. APR-246 is Aprea’s first candidate drug which is undergoing a Phase I clinical study for refractory hematological malignancies and prostate cancer patients in Sweden. APR-246 belongs to a new class of anticancer compounds shown to induce programmed cell death through a p53 mediated mode of action. The compound is currently being tested in a phase I/II clinical trial at seven clinics in Sweden. The study will include approximately 24 patients, and is an open labeled, dose-escalating study on mainly blood cancer patients, but also patients with prostate cancer.
Annette Elmqvist, CEO, states “We are very happy supporting Aprea with additional GMP manufacturing services. This is a true reflection of our vision to build a thriving company with facilities, skills and services that bring high value to life science companies.“
About Unitech Pharma AB
Unitech Pharma, and its wholly owned subsidiary Unitech Biopharma, has more than 20 years experience in bioproduction and provides contract manufacturing services for products used in clinical trials and for commercial sale. Our customers represent both international pharmaceutical companies along with small and mid-sized biotech companies.
Unitech Pharma has invested in a state-of-the-art, flexible bioproduction and fill and finish facility licensed by EMEA. In the pharmaceutical area, medicines are filled in single-use syringes or injection vials while meeting rigorous sterility requirements in accordance with aseptic manufacturing procedures. We can also offer freeze drying. Unitech Pharma can offer customers a truly full-service solution for pharmaceutical manufacture, from process development and bioproduction to fill & finish of commercial products.
For more information contact:
Annette Elmqvist, CEO, Unitech Biopharma AB
Phone: +46 (0)701 851223, E-mail: email@example.com
Lisa Sandberg,VP Marketing & Sales, Unitech Pharma AB
Phone:+46 (0)701 85 1297, E-mail: firstname.lastname@example.org
Aprea AB is a Swedish biotech company founded in 2003 and based on research performed at the Karolinska Institutet, Stockholm, Sweden. The company focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein p53. Aberrations in p53 are common in many various cancer forms and are associated with increased resistance to standard chemotherapy and thus poor prognosis. Aprea is a Karolinska Development AB (publ) portfolio company. The other main owners are Industrifonden, Östersjöstiftelsen and Praktikerinvest.
APR-246 has been developed based upon results from researcher at the Karolinska Institute. The researchers have discovered that the substance is more efficacious in cancer cells than normal cells, which indicates it could produce significantly fewer side effects than conventional cancer treatments. By inducing the protein p53 the compound makes sure that the cellular suicide program is activated to eliminate the cancer cells. This has been shown in laboratories and animal studies with good results. A unique characteristic of the substance is that it can activate p53 even when the gene is inactivated due to a mutation. Cancers with mutated p53 are often resistant to conventional treatment.
For more formation, please contact:
Thomas Uhlin, CEO Aprea AB
Phone: +46 (0)705 335 137, E -mail: email@example.com
Charlotta Liljebris, VP Development Aprea AB
Phone: +46 (0)703 391 534, E-mail: firstname.lastname@example.org